UBS analyst maintained a Buy rating on CSPC Pharmaceutical Group on August 27 and set a price target of HK$11.80. The company’s shares closed last Wednesday at HK$9.68.
In addition to UBS, CSPC Pharmaceutical Group also received a Buy from CMB International Securities’s Jill Wu in a report issued on August 21. However, on August 24, Jefferies maintained a Sell rating on CSPC Pharmaceutical Group (Other OTC: CHJTF).
Based on CSPC Pharmaceutical Group’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of HK$12.52 billion and a net profit of HK$1.31 billion. In comparison, last year the company earned a revenue of HK$12.96 billion and had a net profit of HK$1.33 billion
